Molbio Diagnostics IPO
Bookbuilding IPO | ₹940.00 Cr | Listing at BSE, NSE
IPO Open
Mon, Aug 10, 2026
IPO Close
Wed, Aug 12, 2026
Price Band
₹768.00 to ₹807.00
Market Cap (Pre-IPO)
₹9,299.87 Cr
IPO Details
| IPO Date | Aug 10, 2026 to Aug 12, 2026 |
| Listing Date | Tentative: Aug 17, 2026 |
| Face Value | ₹1.00 per share |
| Price Band | ₹768.00 to ₹807.00 |
| Lot Size | 18 Shares (Minimum: ₹14,526.00) |
| Sale Type | Offer For Sale + Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹940.00 Crores |
| Total Shares Offered | 11,646,246 shares |
| Fresh Issue | 2,480,246 shares |
| Offer For Sale | 9,166,000 shares |
Molbio Diagnostics IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
Molbio Diagnostics IPO Lot Size
Investors can bid for a minimum of 18 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 18 | ₹14,526 |
| Retail (Max) | 13 | 234 | ₹188,838 |
| S-HNI (Min) | 14 | 252 | ₹203,364 |
| S-HNI (Max) | 68 | 1,224 | ₹987,768 |
| B-HNI (Min) | 69 | 1,242 | ₹1,002,294 |
Molbio Diagnostics Financial Information (Restated Consolidated)
Molbio Diagnostics Ltd.'s revenue increased by 42% and profit after tax (PAT) rose by 18% between the financial year ending with March 31, 2026 and March 31, 2025.
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2,148.42 | 1,461.56 | 1,221.06 |
| Total Income | 1,455.17 | 1,027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| EBITDA | 328.24 | 256.64 | 185.09 |
| NET Worth | 1,144.68 | 952.95 | 807.94 |
| Reserves and Surplus | 1,148.84 | 990.84 | 845.48 |
| Total Borrowing | 412.64 | 123.16 | 174.58 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 16.20% |
| ROCE (Return on Capital Employed) | 20.98% |
| RoNW (Return on Net Worth) | 15.23% |
| PAT Margin (Profit After Tax Margin) | 13.48% |
| EBITDA Margin | 24.97% |
| Price to Book Value | 9.55 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 14.56 | 14.24 |
| P/E (x) | 55.43 | 56.67 |
Company Overview
Molbio Diagnostics Ltd. – Company Overview
- Molbio Diagnostics Ltd. is engaged in the research, development, manufacturing, and commercialization of point-of-care (POC) molecular diagnostic solutions for infectious and non-communicable diseases.
- The company has developed its proprietary 'Truenat' platform, a portable PCR-based molecular diagnostics system that delivers accurate test results within an hour.
- Product Portfolio:
- Truenat Molecular Diagnostic Platform
- Molecular Diagnostic Assays (TB, COVID-19, HIV, Hepatitis B & C, HPV, and others)
- Radiology Solutions
- Digital Pathology Solutions
- Breast Health Screening Solutions
- The company operates six manufacturing facilities in India and serves customers in over 90 countries, including government health programs, hospitals, diagnostic laboratories, and international healthcare organizations.
- Backed by strong in-house R&D, patents, global certifications, and strategic acquisitions, the company has established itself as a leading innovator in molecular diagnostics.
- As of March 31, 2026, the company had 1,225 permanent employees.
Company Strengths
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.
Use of Proceeds
| 1) | Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space. | 125.12 |
| 2) | Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 80.81 |
| 3) | General Corporate Purposes | |
| Total | 205.93 |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Molbio Diagnostics IPO Peer Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Molbio Diagnostics Ltd. | 14.77 | 14.77 | 101.51 | - | 14.55 | - | - |
| Poly Medicure Ltd | 31.79 | 31.75 | 306.45 | 52.61 | 10.37 | - | Consolidated |
| Dr. Lal Pathlabs Ltd | 30.24 | 30.20 | 145.00 | 62.20 | 20.78 | - | Consolidated |
| Metropolis Healthcare Ltd | 9.19 | 9.19 | 72.98 | 63.72 | 12.56 | - | Consolidated |
| Vijaya Diagnostic Centre Ltd | 16.81 | 16.79 | 93.02 | 81.02 | 18.07 | - | Consolidated |
Quick Info
| Sector | healthcare and life sciences |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹9,299.87 Cr |
Important Dates
| IPO Open | Aug 10, 2026 |
| IPO Close | Aug 12, 2026 |
| Allotment Date | Aug 13, 2026 |
| Credit to Demat | Aug 14, 2026 |
| Listing Date | Tentative: Aug 17, 2026 |
Lead Manager(s)
Kotak Mahindra Capital Co.Ltd.
Registrar
Description
- IPO Type: Book build issue aggregating to ₹939.70 crores.
- Issue Structure: A combination of fresh issue of 0.25 crore shares aggregating to ₹200.00 crores and offer for sale of 0.92 crore shares aggregating to ₹739.70 crores.
- IPO Dates: The issue opens on August 10, 2026 and closes on August 12, 2026.
- Allotment Date: The allotment is expected to be finalized on August 13, 2026.
- Listing Details: The shares are proposed to be listed on both National Stock Exchange of India and BSE Limited on August 17, 2026.
- Retail Investment Requirement: Minimum 1 lot (18 shares) amounting to approximately ₹14,526 (at the upper price band).
- Issue Price Band: ₹768 to ₹807 per equity share.
- Lot Size: 18 shares per lot.
This IPO offers investors an opportunity to participate in the molecular diagnostics and medical devices sector through a combination of a fresh issue of shares and an offer for sale by existing shareholders.